Novartis AG (NVS)

92.58 -0.50 (-0.54%) USD  |  NYSE  |  Apr 18, 16:00
92.58 0.00 (0.00%) After-Hours: 20:00
More

Novartis Research and Development Expense (Quarterly): 2.567B for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2000. Upgrade now.
Date Value
December 31, 2023 2.567B
September 30, 2023 3.925B
June 30, 2023 2.526B
March 31, 2023 2.794B
December 31, 2022 2.216B
September 30, 2022 2.542B
June 30, 2022 2.498B
March 31, 2022 2.32B
December 31, 2021 1.51B
September 30, 2021 2.38B
June 30, 2021 2.40B
March 31, 2021 2.351B
December 31, 2020 2.333B
September 30, 2020 2.146B
June 30, 2020 2.441B
March 31, 2020 2.06B
December 31, 2019 2.853B
September 30, 2019 2.199B
June 30, 2019 2.051B
March 31, 2019 2.299B
December 31, 2018 2.234B
September 30, 2018 2.147B
June 30, 2018 2.126B
March 31, 2018 1.982B
December 31, 2017 1.919B
Date Value
September 30, 2017 2.239B
June 30, 2017 2.062B
March 31, 2017 2.169B
December 31, 2016 2.584B
September 30, 2016 2.224B
June 30, 2016 2.19B
March 31, 2016 2.041B
December 31, 2015 2.472B
September 30, 2015 2.19B
June 30, 2015 2.206B
March 31, 2015 2.067B
December 31, 2014 2.537B
September 30, 2014 2.161B
June 30, 2014 2.178B
March 31, 2014 2.21B
December 31, 2013 2.486B
September 30, 2013 2.216B
June 30, 2013 2.247B
March 31, 2013 2.297B
December 31, 2012 1.877B
September 30, 2012 2.191B
June 30, 2012 2.285B
March 31, 2012 2.235B
December 31, 2011 2.523B
September 30, 2011 2.475B

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

1.51B
Minimum
Dec 2021
3.925B
Maximum
Sep 2023
2.427B
Average
2.38B
Median
Sep 2021

Research and Development Expense (Quarterly) Benchmarks

Sandoz Group AG --
Amgen Inc 1.534B
AstraZeneca PLC 3.073B
Incyte Corp 444.49M
MorphoSys AG 86.49M